Effectiveness of a Multifactorial Intervention in Frailty Individuals With HIV Infection: HIDRA360
NCT ID: NCT05832164
Last Updated: 2023-09-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
61 participants
INTERVENTIONAL
2022-12-15
2024-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are after a multifactorial intervention:
1. To describe the sociodemographic, viroimmunological and ART exposure factors of fragile individuals compared to pre-fragile and robust individuals.
2. To describe adherence to the Mediterranean diet in frail individuals compared to pre-frail and robust individuals.
3. To describe the presence of anxiety and depression in frail individuals with respect to pre-fragile and robust individuals.
4. To describe the analytical parameters and inflammatory markers of frail individuals with respect to pre-fragile and robust individuals.
5. To describe the diversity and composition of the intestinal microbiota of frail individuals with respect to pre-fragile and robust individuals.
6. To describe the body composition of frail individuals with respect to pre-fragile and robust individuals.
7. To describe the factors associated with progression to frailty or robustness after six months of a multifactorial intervention.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Spanish Cohort of Patients with HIV Infection Older Than 50 Years for the Study of Fragility and Physical Function
NCT03558438
Search for Fragility Indicators Among People Aged 50+ With Chronic HIV Infection
NCT02874118
My Smart Age With HIV: Smartphone Self-assessment of Frailty
NCT02663856
Altering Mechanisms of Frailty in Persons Living With HIV Aged 50 to 65
NCT04321603
Microbiota Footprint and Frailty Phenotype in Virologically Suppressed People Living With HIV
NCT05078957
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Distribution of short videos (10-15', in a number not exceeding 10), focused on the maintenance of a Mediterranean and balanced diet, developed by the nutrition service of our hospital. If the pandemic situation allows it, explanatory sessions will be organized with the same purpose of physical presence.
* Distribution of short videos (10-15', in a number not exceeding 10) focused on the implementation and adherence to a progressive program of aerobic and anaerobic exercise, developed by the physiotherapy service of our hospital. If the pandemic situation allows it, explanatory sessions will be organized for the same purpose of physical presence.
* Review of polypharmacy by the HIV Unit of our hospital.
* Communication with the NGO Avance Positivo for the development of group socialization activities.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multifactorial intervention
HIV patients
Multifactorial intervention
* Adherence to a Mediterranean diet.
* Progressive aerobic and anaerobic exercise program.
* Review of polypharmacy
* Group socialization activities
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multifactorial intervention
* Adherence to a Mediterranean diet.
* Progressive aerobic and anaerobic exercise program.
* Review of polypharmacy
* Group socialization activities
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to sign the informed consent form
* Stable residence in our health area
Exclusion Criteria
* Prognosis of less than one year of life at the discretion of the investigator.
* Inability to complete the study (8 months) as judged by the investigator or the patient
* Presence of Child stage C cirrhosis, end-stage renal failure (Fge by CKD-EPI\<10 mL/min or dialysis in any form), dementia.
* Bone fracture within the last 3 months that interferes with gait or prehensile strength in the judgement of the investigator.
* Diagnosis prior to inclusion in the study of diseases requiring the use of chemotherapy, radiotherapy or non-minor surgery.
* End of chemotherapy or radiotherapy in the three months prior to study entry
* Major surgery in the three months prior to study entry
* Current diagnosis of wasting syndrome
* Active neoplasm at the time of study entry, except for non-melanoma skin cancer or anal carcinoma in situ
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Costa del Sol
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Julian Olalla Sierra
Medical Specialist, Department of Internal Medicine, Hospital Costa del Sol, Marbella (Malaga,) Spain
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Costa del Sol
Marbella, Málaga, Spain
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0368-N-22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.